The dawn of a new era of targeted therapies for heart failure with preserved ejection fraction (HFpEF)

Affiliations

¹ Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan. haradak@jichi.ac.jp.
² Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan.

Editorial

Kenji Harada et al. Hypertens Res. 2022 Jan.

. 2022 Jan;45(1):164-166.

doi: 10.1038/s41440-021-00799-8. Epub 2021 Nov 24.

¹ Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan. haradak@jichi.ac.jp.
² Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan.

No abstract available

Comment on

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.
Kusunose K, Yoshida H, Tanaka A, Teragawa H, Akasaki Y, Fukumoto Y, Eguchi K, Kamiya H, Kario K, Yamada H, Sata M, Node K; PRIZE Study Investigators. Kusunose K, et al. Hypertens Res. 2022 Jan;45(1):106-115. doi: 10.1038/s41440-021-00752-9. Epub 2021 Oct 17. Hypertens Res. 2022. PMID: 34657137 Free PMC article. Clinical Trial.

1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107038 .
1. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20. - DOI
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. - DOI
1. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ, Lam CSP, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39:2780–92. - DOI
1. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–17. - DOI